ReviewSpringer seminars in immunopathology2006
DNA vaccines for HIV: challenges and opportunities.
Review in Springer seminars in immunopathology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 50 citations in OpenAlex.
- Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.The Journal of infectious diseases · 2013Trial
- Funding Strategies to Foster Enabling Basic Science Research in the Development of an HIV Vaccine.Current HIV research · 2026Review
- Preventing monkeypox outbreaks: Focus on diagnosis, care, treatment, and vaccination.Journal of clinical and translational science · 2023Review
- Article
- Article
- Immunogenicity of a novel enhanced consensus DNA vaccine encoding the leptospiral protein LipL45.Human vaccines & immunotherapeutics · 2015Article
- An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.Infection and immunity · 2014Article
- Short noncoding DNA fragments improve the immune potency of electroporation-mediated HBV DNA vaccination.Gene therapy · 2014Article
- Article
- Article
- In vivo electroporation of minicircle DNA as a novel method of vaccine delivery to enhance HIV-1-specific immune responses.Journal of virology · 2014Article
- Serum amyloid P component facilitates DNA clearance and inhibits plasmid transfection: implications for human DNA vaccine.Gene therapy · 2012Article
- Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.The Journal of infectious diseases · 2011Article
- Chikungunya: a potentially emerging epidemic?PLoS neglected tropical diseases · 2010Review
- Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit.Vaccine · 2010Article
- Systemic immunization with CCL27/CTACK modulates immune responses at mucosal sites in mice and macaques.Vaccine · 2010Article
- Plasmids encoding the mucosal chemokines CCL27 and CCL28 are effective adjuvants in eliciting antigen-specific immunity in vivo.Gene therapy · 2010Article
- Plasmid-encoded interleukin-15 receptor alpha enhances specific immune responses induced by a DNA vaccine in vivo.Human gene therapy · 2009Article
- Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine.Journal of leukocyte biology · 2009Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In December 2005, the UNAIDS and WHO reported that the global epidemic known as acquired immunodeficiency syndrome (AIDS) has claimed the lives of more than 25 million adults and children over the past 26 years. These figures included an estimated 3.1 million AIDS-related deaths in 2005. Despite enormous efforts to control the spread of human immunodeficiency virus (HIV) new infection rates are on the rise. An estimated 40.3 million people are now living with HIV, including 4.9 million new infections this past year. Nearly half of new HIV infections are in young people between the ages of 15 and 24. While drug therapies have helped sustain the lives of infected individuals in wealthy regions, they are relatively unavailable to the poorest global regions. This includes sub-Saharan Africa which has approximately 25.8 million infected individuals, more than triple the number of infections of any other region in the world. It is widely believed that the greatest hope for controlling this devastating pandemic is a vaccine. In this review, we will discuss the current state of DNA-based vaccines and how they compare to other vaccination methods currently under investigation. We will also discuss innovative ideas for enhancing DNA vaccine efficacy and the progress being made toward developing an effective vaccine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.